DCGI approves indigenous mRNA Covid jab for emergency use in adults: Report

The Drugs Controller General of India (DCGI) has approved two doses of Pune-based Gennova Biopharmaceuticals’ mRNA Covid-19 vaccine for restricted use in emergency situations for beneficiaries aged above 18 years age group.

It is for the first time ever that this vaccine remains stable during storage even at 2-8 degrees Celsius, sources said on Tuesday.

The Subject Expert Committee (SEC) has recommended Emergency Use Authorisation (EUA) for India’s first mRNA vaccine on Friday meeting, sources said to ANI.

The Subject Expert Committee under India’s drug regulator has found data submitted by Gennova Biopharmaceuticals “satisfactory”.

The company submitted data in the month of April. Then, they submitted more additional data in the month of May.

Earlier in the month of May, Gennova released the statement to ANI regarding updates on submitting phase 3 data which read, “Gennova is in communication with the regulatory agency and submitting all necessary data and information required for the product approval.”

They also said, “Product development, using innovative technologies like mRNA, a fourth-generation vaccine platform is stable at 2-8 degrees Celsius, is a challenging journey during pandemic times.”

The company has conducted phase 2 and phase 3 data trials on 4000 participants to evaluate vaccine safety, immugenicity and tolerability.

The Union Government is committed to accelerating the pace and expanding the scope of Covid-19 vaccination throughout the country. The nationwide Covid-19 vaccination started on January 16, 2021.

The new phase of universalization of Covid-19 vaccination commenced on June 21, 2021. The vaccination drive has been ramped up through the availability of more vaccines, advance visibility of vaccine availability to States and UTs for enabling better planning by them and streamlining the vaccine supply chain.

As part of the nationwide vaccination drive, the Government of India has been supporting the States and UTs by providing them with Covid-19 vaccines free of cost. In the new phase of the universalization of the Covid-19 vaccination drive, the Union Government will procure and supply (free of cost) 75 per cent of the vaccines being produced by the vaccine manufacturers in the country to States and UTs.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor